Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep;75(9):1201-1210.
doi: 10.1007/s00228-019-02696-z. Epub 2019 Jun 14.

Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study

Paul W A Janssen  1   2 , Thomas O Bergmeijer  3   4 , Gert-Jan A Vos  3   4 , Johannes C Kelder  3   4 , Khalid Qaderdan  3   4 , Thea C Godschalk  3   4 , Nicoline J Breet  4   5 , Vera H M Deneer  4   6 , Christian M Hackeng  4   7 , Jurriën M Ten Berg  3   4
Affiliations

Tailored P2Y12 inhibitor treatment in patients undergoing non-urgent PCI-the POPular Risk Score study

Paul W A Janssen et al. Eur J Clin Pharmacol. 2019 Sep.

Abstract

Purpose: The POPular Risk Score was developed for the selective intensification of P2Y12 inhibitor treatment with prasugrel instead of clopidogrel in patients undergoing non-urgent percutaneous coronary intervention (PCI) with stent implantation. This score is based on platelet reactivity (VerifyNow P2Y12 assay), CYP2C19 genotyping, and clinical risk factors. Our aim was to determine if the use of this score in clinical practice is associated with a reduction in thrombotic events without increasing bleeding events.

Methods: In a single-center prospective cohort study, patients with a high risk score were treated with prasugrel and patients with a low risk score with clopidogrel. The risk score-guided cohort was compared with a historic cohort of clopidogrel-treated patients. The endpoint consisted of all-cause death, myocardial infarction, stroke, or stent thrombosis during 1 year of follow-up. TIMI major and minor bleeding events were also analyzed.

Results: The guided cohort contained 1127 patients, 26.9% of whom were switched to prasugrel according to the POPular Risk Score. The historic cohort contained 893 patients. The incidence of the combined thrombotic endpoint was significantly lower in the guided cohort as compared with the historic cohort (8.4% versus 3.7%, p < 0.001). This strategy was safe with respect to bleeding (4.0% versus 1.3%, p < 0.001, for TIMI major or minor bleeding). Results were comparable after multivariate and propensity score matched and weighted analysis.

Conclusion: Selective intensification of P2Y12 inhibitor treatment after non-urgent PCI based on the POPular Risk Score is associated with a reduction in thrombotic events without an increase in bleeding events.

Keywords: CYP2C19; Clopidogrel; P2Y12 inhibitor; Percutaneous coronary intervention; Platelet aggregation; Prasugrel.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Circulation. 2003 Jun 17;107(23):2908-13 - PubMed
    1. J Am Coll Cardiol. 2005 Jan 18;45(2):246-51 - PubMed
    1. Circulation. 2005 May 24;111(20):2560-4 - PubMed
    1. Diabetes. 2005 Aug;54(8):2430-5 - PubMed
    1. Circulation. 2007 May 1;115(17):2344-51 - PubMed

MeSH terms

LinkOut - more resources